Bloomberg Businessweek
Lilly’s Zepbound Cut Risk of Diabetes by 94% in Obese People
Aug 21, 2024
Madison Muller, a Bloomberg News Health Care Reporter, dives into groundbreaking research revealing that Eli Lilly's ZEP Bound can reduce diabetes risk by 94% in obese patients over three years. She discusses the significant long-term health benefits of weight-loss drugs and their role in battling chronic diseases like type 2 diabetes. The conversation also covers the shift from injections to pills in drug delivery and the fierce competition among pharmaceutical firms driving these innovations.
08:19
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Eli Lilly's weight loss drug significantly reduces diabetes risk by 94% in obese patients, revealing the critical health benefits of tackling obesity.
- GLP-1 medications not only aid in substantial weight loss but also present potential advantages for overall health, including heart health improvements.
Deep dives
Gen AI as the New Operating System
Gen AI is poised to become the fundamental framework for the internet, integrating into all products, services, and applications. Businesses are encouraged to start their AI journey to harness the performance enhancements it offers. For instance, Netflix improved its streaming performance by over 350% through the use of Intel's AI accelerators, which outperform rival technologies by 30%. Implementing AI solutions on trusted architectures can significantly boost operational efficiency and effectiveness.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
